HCA Healthcare (HCA) Stock Forecast & Price Target

HCA Healthcare is favorably positioned by its unmatched scale, diversified hospital-and-outpatient footprint, and leading presence in high-growth urban markets, which support durable volume and pricing power across the cycle. The firm’s 3Q26 strength, including about 10% core adjusted EBITDA growth, helped lift FY26 adjusted EBITDA to roughly $15.9B and reflected stronger volumes, better insured revenue per unit, and disciplined cost control. Even with 2027 headwinds from out-of-period Medicaid supplemental payments and HIX pressure, robust free cash flow, leverage in the lower half of the target range, and ongoing share repurchases reinforce a constructive long-term view.

HCA Healthcare is facing a deteriorating fundamental setup because its earnings are being pressured by HIX-to-uninsured migration, adverse payer mix, and reimbursement that lags inflation while government and managed-care payors remain constrained by regulation and budgets. Competitive intensity across hospitals, tighter clinical labor supply, and elevated staffing, professional fee, and supply costs threaten margins, with uninsured volumes already rising to 10.5% of adjusted admissions and driving a roughly $400m 3Q26 EBITDA headwind. Even after solid volumes and a +5% EBITDA beat, management’s flat 2027 earnings commentary versus 2026 signals limited near-term operating leverage as elective surgery weakness, ongoing HIX pressure, and cash flow deterioration weigh on the outlook.